Key facts
- Notable investors include Hefei Industry Investment Group, Hefei Innovation Technology Venture Capital, Anhui Lianyuan Venture Capital, Guoyuan Innovating Investment, Ancheng Capital — 10 tracked in total.
- Status: Privately Held (backing).
Investors
10- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Afana Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Afana Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Afana Biotechnology
Developer of mRNA drug discovery designed for the biotechnological field. The company focuses on the research of nanocarriers and nucleic acid delivery technology and specializes in mRNA purification process and sequence optimization, enabling the development of new vaccines to combat different mutants of Coronavirus.
- Sector
- Healthcare
- HQ
- Hefei, China
- Founded
- 2021
- Website
- rnalfa.com/
- Ownership
- Privately Held (backing)
Afana Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Afana Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Afana Biotechnology in its N-PORT filings yet. We sweep new filings monthly.